Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Original) A compound according to formula (I)



(I)

one of Z_1, Z_2, Z_3, Z_4 and Z_5 is N, one is CR^{1a} and the remainder are CH, or one or two of Z_1, Z_2, Z_3, Z_4 and Z_5 are independently CR^{1a} and the remainder are CH;

R^1 and R^{1a} are independently hydrogen; hydroxy; (C_{1-6})alkoxy unsubstituted or substituted by (C_{1-6})alkoxy, amino, piperidyl, guanidino or amidino any of which is optionally N-substituted by one or two (C_{1-6})alkyl, acyl or (C_{1-6})alkylsulphonyl groups, $CONH_2$, hydroxy, (C_{1-6})alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C_{1-6})alkylsulphonyloxy; (C_{1-6})alkoxy-substituted(C_{1-6})alkyl; halogen; (C_{1-6})alkyl; (C_{1-6})alkylthio; trifluoromethyl; trifluoromethoxy; nitro; cyano; azido; acyl; acyloxy; acylthio; (C_{1-6})alkylsulphonyl; (C_{1-6})alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C_{1-6})alkyl, acyl or (C_{1-6})alkylsulphonyl groups;

provided that when Z_1, Z_2, Z_3, Z_4 and Z_5 are CR^{1a} or CH, then R^1 is not hydrogen;

A is a substituted or unsubstituted 5 membered aromatic heterocyclic ring of formula (C):



(C)

wherein:

W_1 and W_2 are each independently selected from N, O, S, and CR^8;

W_3 is N or C;

W_4 is N, O, S, or CR^8;

each R^8 is independently selected from hydrogen; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; azido; acyl; acyloxy; acylthio; amino, mono- and di-(C_{1-6})alkylamino; and substituted and unsubstituted (C_{1-6})alkoxy, (C_{1-6})alkyl, (C_{3-7})cycloalkyl, aminocarbonyl, (C_{1-6})alkylthio, (C_{1-6})alkylsulphonyl, and (C_{1-6})alkylsulphoxide;

R^2 is hydrogen, or (C_{1-6})alkyl or (C_{2-6})alkenyl optionally substituted with 1 to 3 groups selected from:
amino optionally substituted by one or two (C_{1-4})alkyl groups; carboxy; (C_{1-4})alkoxycarbonyl; (C_{1-4})alkylcarbonyl; (C_{2-4})alkenyloxycarbonyl; (C_{2-4})alkenylcarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C_{1-4})alkyl, hydroxy(C_{1-4})alkyl, aminocarbonyl (C_{1-4})alkyl, (C_{2-4})alkenyl, (C_{1-4})alkylsulphonyl, trifluoromethylsulphonyl, (C_{2-4})alkenylsulphonyl, (C_{1-4})alkoxycarbonyl, (C_{1-4})alkylcarbonyl, (C_{2-4})alkenyloxycarbonyl or (C_{2-4})alkenylcarbonyl; cyano; tetrazolyl; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 5-oxo-1,2,4-oxadiazol-3-yl; halogen; (C_{1-4})alkylthio; trifluoromethyl; hydroxy optionally substituted by (C_{1-4})alkyl, (C_{2-4})alkenyl, (C_{1-4})alkoxycarbonyl, (C_{1-4})alkylcarbonyl, (C_{2-4})alkenyloxycarbonyl,

(C_{2-4})alkenylcarbonyl; oxo; (C_{1-4})alkylsulphonyl; (C_{2-4})alkenylsulphonyl; or (C_{1-4})aminosulphonyl wherein the amino group is optionally substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl;

R^3 is a group -U-R^4 where

U is selected from CH_2, C=O, and SO_2 and

R^4 is a substituted or unsubstituted bicyclic carbocyclic or heterocyclic ring system (A):



(A)

containing up to four heteroatoms in each ring in which

ring (a) is aromatic and ring (b) is aromatic or non-aromatic;

X^1 is C;

X^2 is N or CR^5;

X^3 and X^5 are C;

Y^1 is a 1 to 2 atom linker group, each atom of which is independently selected from N and CR^5;

Y^2 is a 2 to 6 atom linker group, each atom of Y^2 being independently selected from N, NR^7, O, S(O)x, CO, CR^5 and CR^5R^6;

each of R^5 and R^6 is independently selected from: hydrogen; (C_{1-4})alkylthio; halo; carboxy(C_{1-4})alkyl; halo(C_{1-4})alkoxy; halo(C_{1-4})alkyl; (C_{1-4})alkyl; (C_{2-4})alkenyl; (C_{1-4})alkoxycarbonyl; formyl; (C_{1-4})alkylcarbonyl; (C_{2-4})alkenyloxycarbonyl; (C_{2-4})alkenylcarbonyl; (C_{1-4})alkylcarbonyloxy; (C_{1-4})alkoxycarbonyl(C_{1-4})alkyl; hydroxy; hydroxy(C_{1-4})alkyl; mercapto $C_{1-4})$alkyl; (C_{1-4})alkoxy; nitro; cyano; carboxy; amino or wherein the amino group is optionally substituted by (C_{1-4})alkoxycarbonyl, (C_{1-4})alkylcarbonyl, (C_{2-4})alkenyloxycarbonyl, (C_{2-4})alkenylcarbonyl, (C_{1-4})alkyl or (C_{2-4})alkenyl and optionally further substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl; or

(C_{2-6})alkenyl; (C_{1-4})alkylsulphonyl; (C_{2-4})alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally mono- or di-substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl; aryl; aryl(C_{1-4})alkyl; or aryl(C_{1-4})alkoxy;

each R^7 is independently hydrogen; trifluoromethyl; (C_{1-4})alkyl unsubstituted or substituted by hydroxy, (C_{1-6})alkoxy, (C_{1-6})alkylthio, halo or trifluoromethyl; (C_{2-4})alkenyl; aryl; aryl (C_{1-4})alkyl; arylcarbonyl; heteroarylcarbonyl; (C_{1-4})alkoxycarbonyl; (C_{1-4})alkylcarbonyl; formyl; (C_{1-6})alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C_{1-4})alkoxycarbonyl, (C_{1-4})alkylcarbonyl, (C_{2-4})alkenyloxycarbonyl, (C_{2-4})alkenylcarbonyl, (C_{1-4})alkyl or (C_{2-4})alkenyl and optionally further substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl; and
x is 0, 1, or 2;
y is 1, or 2; or a pharmaceutically acceptable salt thereof.

2. (Original) A compound according to claim 1 wherein Z_5 is CH or N, Z_3 is CH or CF and Z_1, Z_2 and Z_4 are each CH, or Z_1 is N, Z_3 is CH or CF and Z_2, Z_4 and Z_5 are each CH.

3. (Original) A compound according to claim 1 wherein R^1 is methoxy and R^{1a} is H or when Z_3 is CR^{1a} it may be C-F.

4. (Currently amended) A compound according to claim 1 wherein ~~heterocyclic~~ heterocyclic ring (C) is substituted or unsubstituted pyrrole, thiophene, furan, thiazole or triazole.

5. (Original) A compound according to claim 1 wherein R^2 is hydrogen or unsubstituted or substituted (C_{1-6})alkyl.

6. (Original) A compound according to claim 1 wherein in the heterocyclic ring (A) Y^2 has 3-5 atoms including NR^7, O or S bonded to X^5 and NHCO bonded via N to X^3, or O or NH bonded to X^3.

7. (Currently amended) A compound according to claim 1 wherein R^4 is selected from:
4*H*-benzo[1,4]thiazin-3-one-6-yl,
4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one-6-yl,
4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one-6-yl,
1,2,3,4-tetrahydro-[1,8]naphthyridine-7-yl,
1*H*-pyrido[3,2-*b*][1,4]thiazin-2-one-7-yl,
4*H*-benzo[1,4]oxazin-3-one-6-yl,
2,3-dihydro-[1,4]dioxino[2,3-c]-pyridin-7-yl, and
6-fluoro-2,3-dihydrobenzo[1,4]dioxine-7-yl.

8. (Original) A compound according to claim 1 which is 3-Oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-sulfonic acid {3-[4-(6-methoxy-[1,5]naphthyridin-4-yl)-[1,2,3]triazol-1-yl]-propyl}amide or 6-{[(2-{4-[6-(methoxy)-1,5-naphthyridin-4-yl]-1,3-thiazol-2-yl}ethyl)amino]methyl}-2*H*-pyrido[3,2-*b*][1,4]thiazin-3(4*H*)-one dihydrochloride
or a pharmaceutically acceptable salt thereof.

9. (Original) A method of treatment of bacterial infections in mammals which comprises the adrninistration to a mammal in need thereof an effective amount of a compound according to claim 1.

10. (Original) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier for use in the treatment of bacterial infections in mammals.

11. (Original) A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier.